Medicare AdvantagePrior AuthMedium impact
MA08.166a, Talquetamab-tgvs (Talvey®)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
May 4, 2026
We identified it
Jun 19, 2026
Summary
Policy MA08.166a establishes medical necessity criteria and coding updates for Talquetamab-tgvs (Talvey®), a targeted cancer therapy. This recent policy change affects how claims for this drug are coded and reviewed for medical necessity under Medicare Advantage plans, effective immediately.
Action Required
By May 4, 2026: Billing team must review and implement MA08.166a medical necessity criteria for Talquetamab-tgvs (Talvey®) claims. Oncology providers and pharmacy staff should verify patient eligibility and documented medical necessity before submitting claims. Update prior authorization requirements in billing system if applicable. Reference the full policy at https://medpolicy.ibx.com/ibc/ma/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=05&FilterField2=MPSiteActivityLogYear&FilterValue2=2026#medicare-advantage-ma08-166a-talquetamab-tgvs-talvey for specific coding and approval criteria. Claims submitted without meeting medical necessity criteria will be denied.